Holen Sie sich die Stockscreener-App
69.59
2.57%
-1.695
Schlusskurs vom Vortag:
$71.29
Offen:
$70.94
24-Stunden-Volumen:
841.89K
Relative Volume:
0.40
Marktkapitalisierung:
$8.17B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
23.04
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
-2.46%
1M Leistung:
+1.60%
6M Leistung:
+18.61%
1J Leistung:
+24.85%
1-Tages-Spanne:
$69.25
$71.90
1-Wochen-Bereich:
$69.25
$72.33
52-Wochen-Spanne:
$47.50
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
69.48 | 8.38B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.88 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.00 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
819.41 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.73 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.29 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance - Insider Monkey
Can Halozyme Therapeutics Inc benefit from deglobalizationWeekly Market Report & Target Return Focused Picks - baoquankhu1.vn
How (HALO) Movements Inform Risk Allocation Models - Stock Traders Daily
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Reframing The Narrative For Halozyme Therapeutics (HALO) After The Latest Analyst Price Target - Yahoo Finance UK
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Share Price Consolidation - Yahoo Finance
Halozyme to preview 2025 revenue, outline 2026-2028 guidance on Jan. 28 - Stock Titan
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade - Insider Monkey
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty - The Globe and Mail
Mizuho Markets Americas LLC Has $25.09 Million Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks - Yahoo Finance
Published on: 2026-01-19 04:05:28 - baoquankhu1.vn
Stephens Investment Management Group LLC Sells 66,796 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen - Chartmill
Assessing Halozyme Therapeutics (HALO) Valuation After New ENHANZE Collaboration With Takeda - Sahm
Campbell & CO Investment Adviser LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
CEO Moves: How liquid is Halozyme Therapeutics Inc stockJuly 2025 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Halozyme Therapeutics (BIT:1HALO) Price Target Increased by 14.97% to 68.41 - Nasdaq
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Does Takeda’s ENTYVIO ENHANZE Deal Reshape The Bull Case For Halozyme Therapeutics (HALO)? - Sahm
Japan's Takeda partners with Halozyme to continue advancing Vedolizumab with ENHANZE® drug-delivery technology - BioSpectrum Asia
Trading Systems Reacting to (HALO) Volatility - Stock Traders Daily
Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy - Indian Pharma Post
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correction2025 Dividend Review & Breakout Confirmation Alerts - Улправда
How Halozyme’s ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Moran Wealth Management LLC Grows Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains - Yahoo Finance
HALO or AXSM: Which Is the Better Value Stock Right Now? - Yahoo Finance
Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio - MSN
Cardinal Capital Management Purchases Shares of 17,768 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Cerity Partners LLC Cuts Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Allspring Global Investments Holdings LLC Has $2.11 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How supply chain issues affect Halozyme Therapeutics Inc. stockPortfolio Risk Report & Consistent Profit Alerts - ulpravda.ru
Will Halozyme Therapeutics Inc. stock see insider buyingDividend Hike & Verified Technical Signals - ulpravda.ru
Is Halozyme Therapeutics Inc. stock ready for breakout2025 Key Highlights & Growth Focused Entry Reports - ulpravda.ru
Can Halozyme Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Review & Daily Momentum Trading Reports - ulpravda.ru
TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
TD Cowen Raises Price Target for HALO to $90.00, Maintains Buy Rating | HALO Stock News - GuruFocus
TD Cowen raises Halozyme Therapeutics stock price target to $90 on growth outlook - Investing.com Canada
Halozyme Partners with Takeda to Develop and Commercialize Vedolizumab - Contract Pharma
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab - Nasdaq
Takeda (TAK) Partners with Halozyme for Enhanced Drug Delivery - GuruFocus
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech - Investing.com
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech By Investing.com - Investing.com Australia
New partnership targets easier ENTYVIO treatment for Crohn’s and colitis - Stock Titan
Why Halozyme Therapeutics Inc. stock remains undervaluedLarge Cap Stability Picks & Low Cost Capital Trading - Улправда
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 43% One-Year Surge? - Sahm
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Haloz - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology By Investing.com - Investing.com Nigeria
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER |
Jan 03 '26 |
Option Exercise |
0.00 |
7,611 |
0 |
38,424 |
2.67%
2.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):